Godavari Biorefineries' anti-cancer patent now validated in Spain and the UK
Godavari Biorefineries announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment.
The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
25 minutes ago
- United News of India
World records third-warmest June, says EU climate service
Brussels, July 9 (UNI) June 2025 was the world's third-warmest June on record, trailing only 2023 and 2024, said the EU-funded Copernicus Climate Change Service (C3S) on Wednesday. The global average surface air temperature in June was 16.46 degrees Celsius, 0.47 degrees above the 1991-2020 average for the month and 1.3 degrees higher than the 1850-1900 pre-industrial level, C3S said in its monthly bulletin. Europe's average temperature for the month was 18.46 degrees, making it the fifth-warmest June on record. Western Europe, however, experienced its warmest June ever, with temperatures averaging 20.49 degrees. "June 2025 saw an exceptional heatwave impact large parts of Western Europe, with much of the region experiencing very strong heat stress," said Samantha Burgess, strategic lead for climate at the European Centre for Medium-Range Weather Forecasts. She warned that heatwaves are likely to become "more frequent, more intense and impact more people across Europe" in a warming world. Beyond Europe, above-average temperatures for June were observed across the United States, northern Canada, central and eastern Asia and West Antarctica. June's global average sea surface temperature (SST) over latitudes from 60 degrees north to 60 degrees south was 20.72 degrees, the third-highest for the month. An "exceptional" marine heatwave developed in the western Mediterranean, where daily SSTs peaked at 27 degrees, the highest ever recorded in the region for June, marking the largest daily SST anomaly globally for any month, C3S noted. "The long-term trend of rising ocean temperatures is evident globally," said Julien Nicolas, senior scientist at C3S. He noted that higher SST poses a rising threat to marine ecosystems and biodiversity as oceans absorb around 90 percent of the excess heat caused by human-induced climate change. Nicolas urged faster action to cut greenhouse gas emissions and to improve climate resilience. "Reducing emissions and adapting our cities and communities to a world with more extreme weather is critical," he said. UNI XINHUA GNK
Mint
a day ago
- Mint
Europe's AI Law Needs a Smart Pause, Not a Full Stop
(Bloomberg Opinion) -- There's a common tool in the arsenal for anyone trying to change the course of artificial intelligence: the pause. Two years ago, Elon Musk and other tech leaders published an open letter calling on tech companies to delay their AI development for six months to better protect humanity. Now the target has shifted. Amid a growing fear of getting left behind in a race to build computers smarter than humans, a group of European corporate leaders are pointing the 'pause' gun at the European Union, the world's self-styled AI cop. Like the tech bros who wanted to rein in AI two years ago, this is a blunt suggestion that misses the nuance of what it's trying to address. A blanket pause on AI rules won't help Europe catch up with the US and China, as more than 45 companies now argue. That ignores a more fundamental problem around funding that the region's tech startups desperately need to scale up and compete with their larger Silicon Valley rivals. The idea that Europe has to choose between being an innovator and a regulator is a narrative successfully spun by Big Tech lobbyists who would benefit most from a lighter regulatory touch. But that doesn't mean the AI act itself couldn't do with a pause, albeit a narrow version of the what firms including ASML Holding NV, Airbus SE and Mistral AI called for in their 'stop the clock' letter published on Thursday, which demands that the president of the European Commission, Ursula von der Leyen, postpone rules they call 'unclear, overlapping and increasingly complex.' On that they have a point, but only for the portion of the 180-page act that was hastily added in the final negotiations to address 'general-purpose' AI models like ChatGPT. The act in its original form was initially drafted in 2021, almost two years before ChatGPT sparked the generative AI boom. It aimed to regulate high-risk AI systems used to diagnose diseases, give financial advice or control critical infrastructure. Those types of applications are clearly defined in the act, from using AI to determine a person's eligibility for health benefits to controlling the water supply. Before such AI is deployed, the law requires that it be carefully vetted by both the tech's creators and the companies deploying it. If a hospital wants to deploy an AI system for diagnosing medical conditions, that would be considered 'high-risk AI' under the act. The AI provider would not only be required to test its model for accuracy and biases, but the hospital itself must have humans overseeing the system to monitor its accuracy over time. These are reasonable and straightforward requirements. But the rules are less clear in a newer section on general-purpose AI systems, cobbled together in 2023 in response to generative AI models like ChatGPT and image-generator Midjourney. When those products exploded onto the scene, AI could suddenly carry out an infinite array of tasks, and Brussels addressed that by making their rules wider and, unfortunately, vaguer. The problems start on page 83 of the act in the section that claims to identify the point at which a general purpose system like ChatGPT poses a systemic risk: when it has been trained using more than 10 to the 25th power — or 10^25 — floating point operations (FLOPs), meaning the computers running the training did at least 10,000,000,000,000,000,000,000,000 calculations during the process. The act doesn't explain why this number is meaningful or what makes it so dangerous. In addition, researchers at the Massachusetts Institute of Technology have shown that smaller models trained with high-quality data can rival the capabilities of much larger ones. 'FLOPs' don't necessarily capture a model's power — or risk — and using them as a metric can miss the bigger picture. Such technical thresholds meanwhile aren't used to define what 'general-purpose AI' or 'high-impact capabilities' mean, leaving them open to interpretation and frustratingly ambiguous for companies. 'These are deep scientific problems,' says Petar Tsankov, chief executive officer of LatticeFlow AI, which guides companies in complying with regulations like the AI act. 'The benchmarks are incomplete.' Brussels shouldn't pause its entire AI law. It should keep on schedule to start enforcing rules on high-risk AI systems in health care and critical infrastructure when they roll out in August 2026. But the rules on 'general' AI come into effect much sooner — in three weeks — and those need time to refine. Tsankov recommends two more years to get them right. Europe's AI law could create some much-needed transparency in the AI industry, and were it to roll out next month, companies like OpenAI would be forced to share secret details of their training data and processes. That would be a blessing for independent ethics researchers trying to study how harmful AI can be in areas like mental health. But the benefits would be short-lived if hazy rules allowed companies to drag their heels or find legal loopholes to get out. A surgical pause on the most ambiguous parts of the act would help Brussels avoid the legal chaos, and make sure that when rules do arrive, they work. More From Bloomberg Opinion: This column reflects the personal views of the author and does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners. Parmy Olson is a Bloomberg Opinion columnist covering technology. A former reporter for the Wall Street Journal and Forbes, she is author of 'Supremacy: AI, ChatGPT and the Race That Will Change the World.' More stories like this are available on
Fibre2Fashion
2 days ago
- Fibre2Fashion
Godavari Biorefineries secures EU patent for anti-cancer molecule
Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB) announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment. Godavari Biorefineries' anti-cancer molecule patent has been validated in Spain, the UK, and as a Unitary Patent in the EU. Now in Phase 1a trials, the molecule shows promise against various cancers. This milestone boosts GBL's scientific innovation presence, led by Sathgen Therapeutics, and supports its broader push into biotech alongside its core bio-based businesses. The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers. "This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research," said Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. "It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation." Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its investment in translational research that addresses some of the world's most urgent health challenges. This development highlights GBL's growing diversification into advanced scientific domains, complementing its leadership in ethanol, bio-based chemicals, and renewable materials produced from agricultural feedstocks. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. ALCHEMPro News Desk (HU)
